A critical platform technology to synthesise drug compounds at scale – and onshore production in Australia – has been successfully demonstrated in a collaboration between Melbourne company Boron Molecular, and innovation and technology development specialists, DMTC Limited, with support from Australia’s national science agency, CSIRO. (more…)
Research with real-world impact, efforts to build the capacity of Australia’s small businesses and breakthroughs in technology development have been recognised with Awards for Excellence at the DMTC Annual Conference for 2024.
Awardees were honoured in seven categories, with each demonstrating commitment to excellence and collaboration across a diverse portfolio of programs and projects. (more…)
The CEO of Australian biotech company Sementis Limited, Dr Anne Collins, has been honoured with the Collaboration Award at the DMTC Annual Conference for 2024.
Often described as the MVP Award, the Collaboration Award honours a leader who embodies the spirit of collaboration that is integral to DMTC’s strategic intent and outlook.
A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis.